SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 657.80+1.7%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biotechwantabe who wrote (3197)1/9/2021 3:27:53 PM
From: A.J. Mullen1 Recommendation

Recommended By
Miljenko Zuanic

  Read Replies (1) of 3557
 
Thanks for that. My immediate response was that 8.5% was better than nothing but not exciting. If however you look at the ratio of deaths, those taking the drugs experienced mortality reduced by (1 - 27.3/35.8) = 24%, which is more interesting.

Even better, Kevzara (sarilumab) did better than Actemra (tocilizumab), Hospital mortality was 28.0% (98/350) for tocilizumab, 22.2% (10/45) for sarilumab and 35.8% (142/397) for control. That's from a pre-print of a paper submitted for review, medrxiv.org.
Using the numbers for Kevzara alone, gives a reduction in mortality of 38%, which doesn't seem too shabby.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News